GlassScriptPhysician profile
David Edward Rogers
NPI 1275547788
$2,368.10
in general payments reported to CMS, 2019-2025
30 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $76.15 · 2021: $256 · 2022: $352 · 2023: $290 · 2024: $380 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.59 | 2019-2025 | |
| Emergent Biosolutions INC. | $344.48 | 2019 | |
| Abbvie INC. | $268.65 | 2021-2025 | |
| Amgen INC. | $206.07 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $159.30 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $138.23 | 2023-2025 | Wegovy, Saxenda, Ozempic |
| Astellas Pharma US INC | $98.58 | 2019-2021 | |
| Amarin Pharma, INC. | $89.73 | 2019-2022 | |
| Exact Sciences Corporation | $76.15 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $71.02 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $63.60 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $50.53 | 2019 | |
| Abbott Laboratories | $43.46 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $41.84 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $34.35 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Elements, INC. | $34.20 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.55 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $30.32 | 2019-2023 | |
| Aerin Medical INC. | $25.83 | 2025 | |
| Inspire Medical Systems, INC. | $25.37 | 2024 | Inspire |
| Bardy Diagnostics, INC. | $23.26 | 2020 | |
| Boston Scientific Corporation | $22.02 | 2024 | |
| Esperion Therapeutics, INC. | $21.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.59 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $21.36 | 2022 | |
| Daiichi Sankyo INC. | $20.96 | 2021 | |
| Antares Pharma, INC. | $17.94 | 2022 | |
| Lilly USA, LLC | $17.04 | 2024 | Mounjaro, Zepbound |
| Tactile Systems Technology INC | $13.83 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.